Early Medication Discontinuation and Long-term Clinical Outcome in FEP

Overview

The study aims to examine the relationship between early maintenance therapy decisions in first episode psychosis, and the subsequent long-term clinical outcome at 9-10 years by comparing a group of patients who were randomized to discontinue (placebo) or continue medication (quetiapine) in the early stage of their psychotic disorders.

Full Title of Study: “The Impact of Early Medication Discontinuation on Long-term Clinical Outcome in First Episode Psychosis”

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: December 2014

Detailed Description

Design: This is a follow up or extension to the double-blind randomized placebo-controlled 12-month study (Chen et al., BMJ 2010;341:C4024-4). At any point during the 12-month study, patients who had relapsed or discontinued would stop the study medication (quetiapine or placebo) and that would be the end point of the randomized phase of the study. After completion of the randomized phase, patients will receive clinical guideline-based, open-label treatment. Trained research assistants will approach patients at their upcoming out-patient consultations to introduce the follow-up study and to obtain their written informed consent. Data analysis plan & handling of missing outcome data: Statistical analyses will be carried out according to the intention-to-treat principle. The primary outcome measure of the long-term clinical outcomes (suicide, clozapine treatment, persistent positive symptoms) between the groups randomized to early treatment discontinuation (placebo) or maintenance treatment (quetiapine) will be compared using risk ratios [RR] and 95% confidence intervals [CI]. For all patients, long-term outcome assessments will include longitudinal chart review over the follow-up period indicating suicide or clozapine treatment. Positive symptom will be assessed at the 10-year face-to-face interview, or in the situations where this data is not available, will be based on the last positive symptom assessment from the randomized study. We will assess the possible effect of this approach by conducting sensitivity analyses, namely re-classifying patients with missing end-point interviews as either all good outcome, or all poor outcome. A mediation analysis will also carried out to examine whether the effects of the intervention on long-term outcome are linked to relapse during the randomized phase. The secondary outcome measures of social and occupational functioning will be analysed using RR or independent t-tests. Standardized mortality ratios (SMRs) based on age-sex population mortality rate and age-sex suicide rate will also be calculated.

Arms, Groups and Cohorts

  • Early maintenance treatment group
    • Drug (quetiapine, 400mg/d) during the 12-month randomized phase of the study
  • Early discontinuation group
    • Drug (placebo) during the 12-month randomized phase of the study

Clinical Trial Outcome Measures

Primary Measures

  • Poor clinical outcome
    • Time Frame: In one month previous to the final assessment
    • Define categorically as any of: persistent positive symptoms of psychosis, requirement for clozapine or death from suicide. Good clinical outcome: meeting none of the criteria for Poor clinical outcome (as above)

Secondary Measures

  • Social and occupational functioning
    • Time Frame: In one month previous to the final assessment
    • Define using employment status, social and occupational functioning score, and role functioning score

Participating in This Clinical Trial

Inclusion Criteria

  • A diagnosis of schizophrenia or non-affective psychosis (schizophreniform disorder, schizoaffective disorder, brief psychotic disorder, or psychosis not otherwise specified) (DSM-IV) – Aged 18 to 65 years – Had been treated with antipsychotic drugs for at least 12 months – No history of relapse or exacerbation or had to be asymptomatic (free of positive symptoms of psychosis) at study entry. Exclusion Criteria:

  • A diagnosis of drug-induced psychosis – Current treatment with clozapine, with mood stabilizing medications (lithium, valproate or carbamazepine) or with depot medication – Had high risk of suicide or violence – Had poor adherence to treatment (missing>50% of drug, >50% missed clinic visits, or a history of medication discontinuation)

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 65 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Professor Eric Y.H. Chen
  • Collaborator
    • Research Grants Council, Hong Kong
  • Provider of Information About this Clinical Study
    • Sponsor-Investigator: Professor Eric Y.H. Chen, Professor – The University of Hong Kong
  • Overall Official(s)
    • Eric YH Chen, MD, Principal Investigator, The University of Hong Kong

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.